These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

58 related articles for article (PubMed ID: 21220251)

  • 1. Playing the numbers game.
    Drug Ther Bull; 2011 Jan; 49(1):1. PubMed ID: 21220251
    [No Abstract]   [Full Text] [Related]  

  • 2. European regulatory body recommends suspension of rosiglitazone.
    Cohen D
    BMJ; 2010 Sep; 341():c5291. PubMed ID: 20870700
    [No Abstract]   [Full Text] [Related]  

  • 3. Rosiglitazone and the need for a new drug safety agency.
    Garattini S; Bertele' V
    BMJ; 2010 Oct; 341():c5506. PubMed ID: 20926483
    [No Abstract]   [Full Text] [Related]  

  • 4. Commentary: What can we learn from the continuing regulatory focus on the thiazolidinediones?
    Freemantle N
    BMJ; 2010 Sep; 341():c4812. PubMed ID: 20819888
    [No Abstract]   [Full Text] [Related]  

  • 5. Licensing drugs for diabetes.
    Lehman R; Yudkin JS; Krumholz H
    BMJ; 2010 Sep; 341():c4805. PubMed ID: 20819887
    [No Abstract]   [Full Text] [Related]  

  • 6. Insiders criticise FDA's decision not to withdraw rosiglitazone.
    Cohen D
    BMJ; 2010 Sep; 341():c5333. PubMed ID: 20880925
    [No Abstract]   [Full Text] [Related]  

  • 7. FDA places greater restrictions on access to rosiglitazone.
    BMJ; 2010 Sep; 341():c5287. PubMed ID: 20870699
    [No Abstract]   [Full Text] [Related]  

  • 8. FDA committees say keep rosiglitazone available but increase warnings.
    Tanne JH
    BMJ; 2007 Aug; 335(7613):223. PubMed ID: 17673743
    [No Abstract]   [Full Text] [Related]  

  • 9. Major US consumer group asks FDA to ban drug for diabetes.
    Tanne JH
    BMJ; 2008 Nov; 337():a2401. PubMed ID: 18987042
    [No Abstract]   [Full Text] [Related]  

  • 10. Avandia panel member may be investigated for possible conflicts of interest.
    Tanne JH
    BMJ; 2010 Aug; 341():c4083. PubMed ID: 20682621
    [No Abstract]   [Full Text] [Related]  

  • 11. Bulletin campaigns against withdrawal of Mixtard 30.
    Hawkes N
    BMJ; 2010 Aug; 341():c4210. PubMed ID: 20685798
    [No Abstract]   [Full Text] [Related]  

  • 12. French doctors demand to know why drug stayed on the market for so long.
    Benkimoun P
    BMJ; 2010 Dec; 341():c6882. PubMed ID: 21131340
    [No Abstract]   [Full Text] [Related]  

  • 13. [Wrong choice of antidiabetics can be disastrous].
    Sjöholm A
    Lakartidningen; 2010 Sep 29-Oct 5; 107(39):2300-1. PubMed ID: 20973243
    [No Abstract]   [Full Text] [Related]  

  • 14. Patient safety first?
    Drug Ther Bull; 2010 Feb; 48(2):13. PubMed ID: 20147430
    [No Abstract]   [Full Text] [Related]  

  • 15. EMA revokes marketing authorization for bufexamac.
    Uter W; Schnuch A
    Contact Dermatitis; 2011 Apr; 64(4):235-6. PubMed ID: 21392031
    [No Abstract]   [Full Text] [Related]  

  • 16. Data openness. Independent public inquiries needed to ensure drug safety.
    Edwards B
    BMJ; 2010 Nov; 341():c6336. PubMed ID: 21081612
    [No Abstract]   [Full Text] [Related]  

  • 17. Drug recalls underscore safety concerns.
    Greene HL
    Health News; 2000 May; 6(5):4. PubMed ID: 10851966
    [No Abstract]   [Full Text] [Related]  

  • 18. Revisiting the rosiglitazone story--lessons learned.
    Rosen CJ
    N Engl J Med; 2010 Aug; 363(9):803-6. PubMed ID: 20660395
    [No Abstract]   [Full Text] [Related]  

  • 19. Rosiglitazone.
    Diabetes Obes Metab; 2000 Apr; 2(2):117. PubMed ID: 11220523
    [No Abstract]   [Full Text] [Related]  

  • 20. Warner-Lambert voluntarily withdraws Rezulin.
    Diabetes Technol Ther; 2000; 2(2):290. PubMed ID: 11469273
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.